Clinical Trials Browser

Phase 2 × Erlotinib Hydrochloride × Breast × Clear all

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT00597597 2023-05-17

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Phase 2 Terminated

11 enrolled 12 charts

Breast Neoplasms

NCT00570258 2021-03-30

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Phase 2 Terminated

27 enrolled 7 charts

Breast Neoplasms

NCT00733408 2018-12-04

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Phase 2 Completed

59 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00054132 2017-07-24

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Phase 2 Completed

38 enrolled 10 charts

Breast Neoplasms

NCT00491816 2017-01-19

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

Phase 2 Unknown

Breast Neoplasms, Neoplasms

NCT00059852 2016-12-07

Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00054275 2016-02-17

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Phase 2 Completed

39 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00109265 2015-07-02

A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

Phase 2 Completed

Breast Neoplasms, Neoplasms

NCT01013506 2013-05-23

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Phase 2 Terminated

11 enrolled 9 charts

Hormone-sensitive Metastatic Breast Cancer

NCT00633750 2012-09-05

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

50 enrolled 9 charts

Breast Neoplasms

NCT00611715 2012-08-09

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

Phase 2 Terminated

48 enrolled 11 charts

Breast Neoplasms

NCT00739063 2012-03-15

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Phase 2 Terminated

11 enrolled 5 charts

Breast Neoplasms